Balance Sheet
Cash Flow Statement
Asset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther financing activitiesSales of Property, Plant and EquipmentShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Senti Biosciences (SNTI) Change in Cash (2021 - 2025)

Senti Biosciences (SNTI) has 5 years of Change in Cash data on record, last reported at -$9.3 million in Q3 2025.

  • For Q3 2025, Change in Cash fell 73.72% year-over-year to -$9.3 million; the TTM value through Sep 2025 reached $1.7 million, up 105.48%, while the annual FY2024 figure was $12.4 million, 157.42% up from the prior year.
  • Change in Cash reached -$9.3 million in Q3 2025 per SNTI's latest filing, up from -$12.2 million in the prior quarter.
  • Across five years, Change in Cash topped out at $101.7 million in Q2 2022 and bottomed at -$57.2 million in Q4 2022.
  • Average Change in Cash over 5 years is -$2.3 million, with a median of -$7.4 million recorded in 2023.
  • The widest YoY moves for Change in Cash: up 9167.98% in 2022, down 6537.26% in 2022.
  • A 5-year view of Change in Cash shows it stood at $889323.0 in 2021, then plummeted by 6537.26% to -$57.2 million in 2022, then soared by 88.86% to -$6.4 million in 2023, then surged by 692.08% to $37.8 million in 2024, then tumbled by 124.68% to -$9.3 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Cash were -$9.3 million in Q3 2025, -$12.2 million in Q2 2025, and -$14.5 million in Q1 2025.